Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: treat-to-target

Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support

Gretchen Henkel  |  July 1, 2014

Rheumatologists at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco outline disease classification criteria, treat-to-target approach to lupus

Filed under:Biologics/DMARDsConditionsDrug UpdatesEULAR/OtherMeeting ReportsSystemic Lupus Erythematosus Tagged with:AC&RAmerican College of Rheumatology (ACR)BiologicsdrugEULARGlucocorticoidsLupusprednisoneRheumatoid arthritisrheumatologistrituximabSLESystemic lupus erythematosus

Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk

Kathy Holliman  |  March 1, 2014

Experts question how to apply the new American College of Cardiology and American Heart Association guidelines in patients with rheumatic disease and call for further validation of the risk assessment algorithm

Filed under:Career DevelopmentConditionsEducation & TrainingProfessional TopicsResearch RheumRheumatoid Arthritis Tagged with:cardiovascularClinical Guidelinespatient careResearchRheumatic DiseaseRheumatoid arthritisrheumatologistriskStatin

Treat-to-Target Decisions and Dilemmas

David S. Pisetsky, MD, PhD  |  July 12, 2011

A better understanding of targets can lead to better outcomes down the road

Filed under:Education & TrainingOpinionRheuminationsSpeak Out Rheum Tagged with:Diagnosispatient carerheumatologistTreat-to-Target

Kidney Biopsy in Lupus Nephritis

Ruth Jessen Hickman, MD  |  May 31, 2025

As part of a session on lupus nephritis at ACR Convergence 2023, Simone Appenzeller, MD, PhD, shared perspectives on the importance of biopsy to inform the diagnosis, prognosis and treatment of the condition, with an emphasis on childhood disease. Prompt diagnosis and treatment of lupus nephritis is perhaps even more important for children than for…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:kidney biopsyLupus nephritis supplement

Nature vs. Nurture & Their Roles in Autoimmunity

Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS  |  May 12, 2025

They looked exactly alike—tall, slightly scruffy gentlemen with denim overalls lightly stained with dirt and oil, with dusty trucker hats to match. The only difference was that one wore a red checkered shirt and the other wore a green one. Yet these similarities were deceptive. The one closest to me was the patient, the one…

Filed under:OpinionRheuminations Tagged with:DNAepigeneticsgenetic riskgenetics

Precision Medicine on a Population Level

Daniel H. Solomon, MD, MPH, & Andrew Concoff, MD, FACR  |  February 6, 2025

Guest columnists Dr. Daniel Solomon & Dr. Andrew Concoff discuss the potential of technology, such as mobile health apps, to enhance remote care & improve access for underserved patients.

Filed under:OpinionPractice ManagementPractice SupportSpeak Out RheumTechnologyWorkforceWorkforce Tagged with:healthcare accessPrecision Medicine

Precision Medicine on a Population Level: Can Digital Health Technology Improve Access to Rheumatologic Care?

Daniel H. Solomon, MD, MPH, & Andrew Concoff, MD, FACR  |  January 16, 2025

Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…

Filed under:ConditionsOpinionPractice SupportRheumatoid ArthritisSpeak Out RheumTechnology Tagged with:mPROscheduling app

Prevalence of Fibromyalgia & Widespread Pain in Psoriatic Arthritis: Association with Disease Severity Assessment in a Large U.S. Registry

Philip Mease, George Reed, Alexis Ogdie, Dimitrios A. Pappas, & Joel M. Kremer  |  December 9, 2024

According to a new study, fibromyalgia prevalence is elevated in PsA and is associated with elevated disease measures, confounding reliable disease assessment for treat-to-target goals.

Filed under:American College of RheumatologyConditionsPsoriatic ArthritisResearch Rheum Tagged with:FibromyalgiaPsA Resource CenterPsoriatic Arthritis

MCTD: Is It Just Letters?

Ruth Jessen Hickman, MD  |  December 4, 2024

At a Great Debate session, speakers discussed whether mixed connective tissue disease is a distinct disease entity in rheumatology.

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2024connective tissue diseasemixed connective tissue disease (MCTD)

Top Research in Rheumatoid Arthritis Presented at ACR Convergence 2024

Jeffrey Curtis, MD, MS, MPH  |  December 3, 2024

Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 RA

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 18
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences